HCA
MXCT icon

Harbor Capital Advisors’s MaxCyte MXCT Stock Holding History

Harbor Capital Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,652
Closed -$25.9K – 578
2023
Q2 		$25.9K Buy
+5,652
New +$26K 0.01% 556

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbor Capital Advisors's MXCT Position: Q3 2023 in Review

Harbor Capital Advisors sold out of MaxCyte (MXCT) in Q3 2023, closing a stake of 5,652 shares — an estimated $25.9K sold.

Harbor Capital Advisors first reported a position in MXCT in Q2 2023 and held it in 1 quarter. The position peaked at $25.9K in Q2 2023. 120 funds tracked by Wall St. Rank hold MXCT as of Q3 2023.

  • Harbor Capital Advisors reported no remaining MaxCyte position as of Q3 2023 after selling out during the quarter.
  • Harbor Capital Advisors sold 5,652 MaxCyte shares in Q3 2023, an estimated $25.9K.
  • Harbor Capital Advisors first reported a position in MaxCyte in Q2 2023 and held it in 1 quarter.
  • Harbor Capital Advisors's MaxCyte position peaked at $25.9K in Q2 2023.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q3 2023.

Based on Harbor Capital Advisors's 13F filing for Q3 2023, filed 20 Oct 2023.